• SEC Filings

On May 12, the Board of Directors (“Board”) of the Company, upon the recommendation of its Nominating and Governance Committee, appointed Albert D. Bolles, Ph.D. to serve as a director of the Company and a member of the Board’s Nominating and Governance Committee. Dr. Bolles will serve as a Class I director and will stand for re-election at the Company’s 2019 Annual Meeting of Stockholders.

Dr. Bolles, age 60, served as the executive vice president, chief technology and operations officer at ConAgra Foods until his retirement in August 2015. He previously led worldwide research and development for PepsiCo Beverage and Foods and held senior positions with Gerber Foods and General Foods Corporation. Dr. Bolles earned Ph.D. and M.S. degrees in food science and a bachelors’ degree in microbiology from Michigan State University.

Dr. Bolles has (i)no arrangements or understandings with any other person to which he was appointed to as a director of the Company, and (ii)no family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer. Dr. Bolles does not have any relationship or related transaction with the Company that would require disclosure to Item 404(a) of Regulation S-K under the Securities Act of 1933, as amended.

In connection with his service as a new director, Dr. Bolles will receive the standard compensation paid by the Company to all of its non-employee directors, including an initial option grant issued on appointment as director, and an annual cash retainer and an annual option grant each issued upon the date of each of the Company’s Annual Meeting of Stockholders. This standard non-employee director compensation, a portion of which will be pro-rated to reflect the actual time Dr. Bolles will serve on the Company’s Board this year, is described under the heading of “Non-Employee Director Compensation Policy” in the Company’s Proxy Statement for its Annual Meeting of Stockholders filed with the Securities and Exchange Commission (“SEC”) on April 26, 2017. In connection with his appointment, Dr. Bolles will enter into the standard indemnification agreement with the Company in the form filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 17, 2015 and incorporated by reference herein.

The Company issued a press release on May 15, 2018 announcing the appointment of Dr. Bolles to the Company’s Board. A copy of the press release is attached as Exhibit 99.1 to this report and incorporated by reference herein.

Arcadia Biosciences, Inc. Exhibit
EX-99.1 2 rkda-ex991_6.htm EX-99.1 rkda-ex991_6.htm Exhibit 99.1       FOR IMMEDIATE RELEASE   Media Contact:    Jeff Bergau [email protected] +1-312-217-0419     Albert D. Bolles,…
To view the full exhibit click here

About Arcadia Biosciences, Inc. (NASDAQ:RKDA)

Arcadia Biosciences, Inc. is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market. Its crop yield traits are utilized by its partners to develop higher yielding seeds for global crops, including wheat, rice, soybean, corn, and sugarcane, as well as for other crops, such as cotton, turf and trees. The Company’s portfolio of agricultural productivity traits includes Nitrogen Use Efficiency (NUE), Water Use Efficiency (WUE), Drought Tolerance (DT), Salinity Tolerance (ST) and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada.